Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
Summary
HRES1285 is a non-binding sense-of-the-House resolution expressing support for evidence-based access to mifepristone. It has no legal force, no funding, and no regulatory mechanism. The bill is in early stage, referred to committee, and poses no direct market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HRES1285 is a non-binding resolution with zero legal or financial impact.
- 2.No funding, no regulatory change, no market signal.
- 3.Investors should ignore this bill for portfolio decisions.
Market Implications
No market implications. The resolution does not alter FDA authority, drug access, or company revenues. Investors should not adjust positions based on this bill.
Full Analysis
- On May 14, 2026, Rep. DeGette introduced HRES1285, a sense-of-the-House resolution affirming that over 25 years of evidence supports mifepristone's safety and that access should be based on science. The bill was referred to the House Energy and Commerce Committee. It is an early-stage, non-binding resolution. 2) There is no money trail. The resolution does not authorize or appropriate any funds. It does not change FDA authority, REMS requirements, or any existing law. It is purely an expression of congressional opinion. 3) Because the resolution has no binding effect, there are no structural winners or losers. Companies involved in reproductive health (e.g., $PFE, which manufactures mifepristone under a REMS, or $DAN, which distributes it) face no change in regulatory or revenue environment. 4) No real market data is provided for healthcare stocks. The competitive landscape for mifepristone remains unchanged—generic versions exist, and the drug is subject to FDA REMS restrictions that have been litigated separately. 5) The resolution must pass the House and Senate to be adopted, but even if passed, it carries no legal weight. The companion bill SRES732 is also in early committee stage. No further legislative action is expected in the near term.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
A resolution expressing the sense of the Senate to reduce traffic fatalities to zero by 2050.
A resolution expressing the sense of the Senate regarding critical elements of the United States policy towards the People's Republic of China.
Expressing the sense of the House of Representatives in support of Prime Minister Benjamin Netanyahu's initiative to transition the United States-Israel relationship toward mutual defense cooperation and joint economic investment, recognizing the contributions of Israel to joint military operations against Iran, and condemning the global rise of antisemitism.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.